KAT681
KAT681 is a liver-selective thyromimetic.
For research use only. We do not sell to patients.
- CAS No.: 373641-87-3
- Formula: C24H21FNNaO6
- Molecular Weight:461.41
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
Thyroid Hormone Receptor[1]
In Vitro
The impact of the liver-selective thyromimetic KAT681 (T-0681) is investigated on lipoprotein metabolism. Prolonged treatment with KAT681 increases the hepatic expression of both low-density lipoprotein (LDL) receptor and scavenger receptor class B, type I without affecting cholesteryl ester transfer protein activity. Western blot showing human SR-BI (CLA-1) expression in normal HepG2 cells and in HepG2 cells loaded with AcLDL and subsequently incubated with vehicle or KAT681. SR-BI protein expression is markedly downregulated by incubation with 50 μg/mL AcLDL. This effect can not be reversed by addition of KAT681[1]
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 373641-87-3
-
Molecular Weight 461.41
-
Formula C24H21FNNaO6
-
SMILES
O=C(CC(NC1=CC(C)=C(C(C)=C1)OC2=CC=C(C(C(O)C3=CC=C(C=C3)F)=C2)O)=O)O[Na]
-
Synonyms
T0681
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Tancevski I, et al. The thyromimetic T-0681 protects from atherosclerosis. J Lipid Res. 2009 May;50(5):938-44. [Content Brief]
[2]. Tancevski I, et al. The liver-selective thyromimetic T-0681 influences reverse cholesterol transport and atherosclerosis development in mice. PLoS One. 2010 Jan 15;5(1):e8722. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)